In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS. In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
bronchopulmonary dysplasia(BPD)
Timeframe: at 36 weeks' gestational age or before discharge from hospital
death
Timeframe: at 36 weeks' gestational age or before discharge from hospital
BPD and/or death
Timeframe: at 36 weeks' gestational age or before discharge from hospital
the predictive powers of one dose of surfactant to diagnose NRDS
Timeframe: seven days after birth
the predictive powers of two and more doses of surfactant to diagnose NARDS
Timeframe: seven days after birth